Clinical Trials Webinar Series - Review of Radiopharmaceuticals Used in Radionuclide Therapy
Clinical Trials Webinar Series - Review of Radiopharmaceuticals Used in Radionuclide Therapy
Clinical Trials Webinar Series - Review of Radiopharmaceuticals Used in Radionuclide Therapy
 

Technologist (VOICE) Member Fee: Free
Technologist (VOICE) Non-Member Fee: $32.00

Physician (AMA) Member Fee: Free

Physician (AMA) Non-Member Fee: $49.00

Pharmacist (ACPE) Member Fee: Free
Pharmacist (ACPE) Non-Member Fee: $40.00

 
Release Date: November 14, 2019
Expiration Date: November 30, 2022

Presenters
Michael Graham, MD and Yusuf Menda, MD

Financial Disclosure 

Name 

Role 

Disclosure 

Michael Graham, PhD, MD 

Faculty 

Nothing to Disclose 

Yusuf Menda, MD

Faculty

Ran Scientific Study/Trials for Novartis Pharmaceuticals

Jonathan McConathy, MD, PhD

CTN Co-Chair

Consultant/Advisor for Eli Lilly/Avid, Blue Earth Diagnostics, GE Healthcare and ran Scientific Study/Trials for AbbVie, Navidea, Alphasource and ImaginAb

John Sunderland, PhD, MBA

CTN Co-Chair

Nothing to Disclose 

John Hoffmann, MD 

CTN Education Organizer 

Consultant/Advisor and ran Scientific Study/Trials for GE healthcare and Blue Earth Diagnostics 

Amanda Abbott

Planner/Moderator

Nothing to Disclose 

Bonnie Clark 

Director, SNMMI CTN 

Nothing to Disclose 

Tina Kiss

CTN Staff 

Nothing to Disclose 

Asween Marco

CTN Staff 

Nothing to Disclose 

Bennett Greenspan, MD

CE Reviewer 

Nothing to Disclose 

Arnold M. Strashun, MD 

Chair, Continuing Education Committee 

Nothing to Disclose 

Delicia Hurdle

SNMMI Staff, Education 

Nothing to Disclose 

No Commercial Support was received for this activity 

In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the planners and faculty have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity. 

 

Target Audience

Nuclear medicine physicians, pharmacists, technologists and residents/student 


Objectives
At the completion of this activity, the participant will be able to:
  1. List the radiopharmaceutials used to perform SPECT MPI and discuss how each is best utilized
  2. Outline the mechanism of action for the approved radiotherapy drugs discussed in this webinar
  3. Name the categories of drugs that reduce catecholamine uptake and state how they may affect 131I-MIBG therapy
  4. List the radiopharmaceuticals available for prostate cancer radiotherapy and describe how they are best used
  5. Summarize the radiotherapy drugs that are in the pipeline and present their describe applications


Continuing Education Credit Information


Physician (AMA-PRA Category 1 Credits TM):
The Society of Nuclear Medicine and Molecular Imaging Inc., (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.  

SNMMI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation. Learners will have no more than 3 attempts to successfully complete the post-test. This activity must be completed by the expiration date listed above.

Image result for ACPE logo

Pharmacist (ACPE):
The Society for Nuclear Medicine and Molecular Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been designated as knowledge-based CPE. Learners will successfully complete the CPE activity and be awarded credit upon completion of the activity evaluation form and post-assessment test, which will be sent out after the program. The universal program number for this meeting is 0210-0000-019-971-H04-P. Total available credit for pharmacists is 1.0 hours or 0.1 CEUs.


Technologist (VOICE A+):

The SNMMI, through its Verification of Involvement in Continuing Education (VOICE) program, has approved this meeting for a maximum of 1.0 continuing education hours (CEHs). VOICE-approved credit is recognized by most licensure states and by the NMTCB and ARRT as Category A+ credit. To receive CE credit, learners must first complete the activity content, achieve a score of 80% on the post-course assessment and complete the evaluation. Learners will have no more than 3 attempts to successfully complete the post-test. This activity must be completed by the expiration date listed above. California Scope: 1.0 Radiopharmacy (R).

Minimum system requirements 

- Supported Internet Browsers: 
- Microsoft Internet Explorer (version 7 or higher) 
- Google Chrome (latest version) 
- Mozilla Firefox (latest version) 
- Apple Safari (version 4 or higher) 
 

Plug-in: Adobe Acrobat Reader (http://get.adobe.com/reader/)  
 
For questions please contact the Education Department 703-708-9000 x1. 
© 2019 SNMMI. All rights reserved.  
 
For more information on our privacy policy, please click the link below. 

 





Type:     Internet Activity (Enduring Material)
189 Registered Users